Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,653 Million (Large Cap)
46.00
NA
1.05%
-0.32
16.07%
4.99
Revenue and Profits:
Net Sales:
641 Million
(Quarterly Results - Mar 2026)
Net Profit:
162 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.54%
0%
-15.54%
6 Months
-14.56%
0%
-14.56%
1 Year
6.62%
0%
6.62%
2 Years
31.55%
0%
31.55%
3 Years
25.34%
0%
25.34%
4 Years
22.91%
0%
22.91%
5 Years
-35.04%
0%
-35.04%
Double Medical Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.93%
EBIT Growth (5y)
-3.02%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.53
Tax Ratio
10.39%
Dividend Payout Ratio
57.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.11%
ROE (avg)
13.80%
Valuation key factors
Factor
Value
P/E Ratio
46
Industry P/E
Price to Book Value
6.99
EV to EBIT
47.74
EV to EBITDA
31.14
EV to Capital Employed
9.21
EV to Sales
8.98
PEG Ratio
0.18
Dividend Yield
0.80%
ROCE (Latest)
19.28%
ROE (Latest)
15.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
641.50
724.60
-11.47%
Operating Profit (PBDIT) excl Other Income
167.90
220.40
-23.82%
Interest
1.30
1.30
Exceptional Items
10.60
5.80
82.76%
Consolidate Net Profit
161.90
188.10
-13.93%
Operating Profit Margin (Excl OI)
261.80%
221.80%
4.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -11.47% vs 8.83% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -13.93% vs -0.79% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,571.30
2,116.50
21.49%
Operating Profit (PBDIT) excl Other Income
806.10
545.80
47.69%
Interest
6.90
6.90
Exceptional Items
43.90
3.60
1,119.44%
Consolidate Net Profit
636.90
385.30
65.30%
Operating Profit Margin (Excl OI)
219.70%
152.90%
6.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 21.49% vs 38.84% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 65.30% vs 346.47% in Dec 2024
About Double Medical Technology, Inc. 
Double Medical Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






